Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases

Michael Koutsilieris, Constantine S. Mitsiades, John Bogdanos, +4

Clinical Cancer Research

Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.

Constantine S. Mitsiades, John Bogdanos, Dimitrios Karamanolakis, +3

PubMed

The large bladder diverticulum in children

John Bogdanos, Ilias Paleodimos, Georgios Korakianitis, +2

Journal of Pediatric Urology

UrologyLarge Bladder DiverticulumGastroenterologyPediatricsPediatric Gastroenterology +2

Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.

John Bogdanos, Dimitrios Karamanolakis, Constantine Milathianakis, +3

PubMed

Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).

Dimitrios Karamanolakis, Theocharis Lambou, John Bogdanos, +8

PubMed

Urogenital RadiologyUrologyAndrologyAdjunct TestCancer Detection +12

Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.

John Bogdanos, Dimitrios Karamanolakis, Konstantinos N. Milathianakis, +6

PubMed

Morbidity of prophylactic inguinal lymphadenectomy with saphenous vein preservation for squamous cell penile carcinoma

Constantine Milathianakis, John Bogdanos, Dimitrios Karamanolakis

International Journal of Urology

Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy

Peter Lembessis, Pavlos Msaouel, Antonis Halapas, +10

Clinical Chemistry and Laboratory Medicine (CCLM)

Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement

Dimitrios Karamanolakis, John Bogdanos, Antigone Sourla, +5

Molecular Medicine

RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER

M. Koutsilieris, C Mitsiades, John Bogdanos, +4

European Urology Supplements

UrologyGenitourinary CancerMedicinePharmacotherapyCancer Treatment +3